The role of 18 F-FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy.

Guanyun Wang,Wenwen Zhang,Xiaohui Luan,Zhanbo Wang,Jiajin Liu,Xiaodan Xu,Jinming Zhang,Baixuan Xu,Shichun Lu,Ruimin Wang,Guangyu Ma

Frontiers in immunology（2023）

引用 0|浏览7

暂无评分

摘要

F-FDG PET is a valuable tool for predicting pathological response and prognosis of unresectable HCC patients treated by Lenvatinib combined with PD-1 as a conversion therapy.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要